HONG KONG, July 14, 2021 /PRNewswire/ — Endurance RP Limited (“Endurance Longevity” or the “Company” and together with its subsidiaries, the “Group”; stock code: 0575.HK) is pleased to announce its wholly owned subsidiary Deep Longevity, Inc, (“Deep Longevity”) a leading provider of deep biomarkers of aging and longevity has launched its MindAge© psychological aging clock and announced the formation of a Scientific Advisory Board (SAB) comprised of certain experts in longevity biotechnology.
MindAge© psychological aging clock
Deep Longevity has been developing a broad range of biomarkers of aging to maintain physical health and wellness, restore youthfulness, and improve mental health and well-being. In this respect, the Group has launched its MindAge© psychological aging clock.
The MindAge tests are now available via the Deep Longevity website and via the Young.AI iPhone app available in the Apple Appstore. It builds on the recently published paper titled “PsychoAge and SubjAge: Development of Deep Biomarkers of Psychological and Subjective Age Using Artificial Intelligence“.
The new survey-based MindAge test is available at https://www.young.ai/mind-age.
Science Advisory Board (SAB)
Chaired by Alex Zhavoronkov, PhD, the Chief Longevity Officer of Deep Longevity, the SAB will help direct and review the company’s work in the development and applications of deep biomarkers of human aging. It includes some of the most outstanding and credible researchers and doctors in the field working in the nascent field of longevity biotechnology and longevity medicine and is comprised of the following individuals:
Eric Verdin, MD, CEO of the Buck Institute for Research on Aging
Daniel Kraft, MD, Standord & Harvard trained physician-scientist. Founder of Exponential Medicine. Chair, XPrize Pandemic Alliance Task force
Morten Scheibye-Knudsen, MD, PhD, head of the biology of aging laboratory and professor at the University of Copenhagen
Vadim Gladyshev, PhD, professor, Head of the Gladyshev Laboratory at Harvard University
Wei-Wu He, PhD, Chairman of Human Longevity, Inc
Among the board, Deep Longevity executed two Consulting Agreements with recognised leaders in the fields of longevity biotechnology and longevity medicine, Dr Verdin and Dr Gladyshev in respect of the provision of scientific and business advisory services to Deep Longevity. They will receive an award of 1,670,000 and 1,110,000 Consultant Shares, respectively, which shares will be subject to certain vesting conditions.
Jim Mellon, Chairman of the board of directors of Endurance Longevity commented, “The scientific advisors of Deep Longevity are some of the highest-impact scientists, medical doctors, and most well-known experts in longevity. Under their leadership and supervision, the company will continue developing and commercializing the biological and psychological aging clocks and engaging in research with the academic and medical institutions as well as with the insurance companies worldwide”.
Alex Zhavoronkov, founder and Chief Longevity Officer, of Deep Longevity said, “Productive longevity is the most important asset we have in this life and Deep Longevity is dedicated to the measurement of aging at every level from biological to psychological. I am very happy to see the company expanding into the psychology of aging as it impacts our physical and mental health and well-being and is one of the areas we can control and intervene in.”
About Deep Longevity
Deep Longevity is a wholly owned subsidiary of Endurance Longevity (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers.
About Endurance Longevity (Stock code: 0575.HK)
Endurance RP Limited is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 23 years of financial reporting since its initial public offering in May 1997.
